NeuroBo Pharmaceuticals (NASDAQ: NRBO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.110 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of NeuroBo Pharmaceuticals (NASDAQ: NRBO) through any online brokerage.
Other companies in NeuroBo Pharmaceuticals’s space includes: Immuron (NASDAQ:IMRN), Cyclacel Pharmaceuticals (NASDAQ:CYCC), BioRestorative Therapies (NASDAQ:BRTX), Calithera Biosciences (NASDAQ:CALA) and Biophytis (NASDAQ:BPTS).
The latest price target for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was reported by HC Wainwright & Co. on Monday, February 1, 2021. The analyst firm set a price target for 16.00 expecting NRBO to rise to within 12 months (a possible 3291.99% upside). 0 analyst firms have reported ratings in the last year.
The stock price for NeuroBo Pharmaceuticals (NASDAQ: NRBO) is $0.4717 last updated June 30, 2022, 8:00 PM UTC.
There are no upcoming dividends for NeuroBo Pharmaceuticals.
NeuroBo Pharmaceuticals’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for NeuroBo Pharmaceuticals.
NeuroBo Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.